Greenwich LifeSciences (GLSI) said Thursday that its board of directors has extended the lock-up period for shares owned by its directors, officers, and existing pre-IPO investors.
The biopharmaceutical company said it has extended the lockup until March 31, 2026, or roughly five and a half years after the company's IPO.
Officers, directors, and certain shareholders will be unable to sell their shares during the lock-up period, unless the board modifies it, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.